Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
Submitted by
admin
on October 11, 2021 - 10:25am
Source:
Yahoo Finance
News Tags:
Protagonist Therapeutics
clinical trials
FDA
rusfertide
polycythemia
Headline:
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
snippet:
All ongoing clinical trials of rusfertide to resume dosing
Phase 3 registrational trial planned to commence in the first quarter of 2022
Conference call scheduled for today at 8:00 A.M. ET
Do Not Allow Advertisers to Use My Personal information
